| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6cb2a104c151e8c41064b273a3ff4058 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-90694 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y107-03003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M5-168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5308 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-44 |
| filingDate |
2016-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2856bc4cccc02354d2793d46c5d7007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_200d940c2540c6905c5be4794122db5c |
| publicationDate |
2016-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016377604-A1 |
| titleOfInvention |
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| abstract |
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11345899-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10160958-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021042055-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9885024-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11781119-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10823727-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11598767-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10731139-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11639927-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9926537-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9926538-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10139399-B2 |
| priorityDate |
2009-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |